Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical's Chief Commercial Officer Cindy Reiss-Clark departs, effective March 7

Neutral Impact 3 of 5 leadership Written later

West Pharmaceutical Services said Chief Commercial Officer Cindy Reiss-Clark left the company effective March 7, 2025. Aileen Kinsella, Head of Proprietary Product Sales, will manage the role's responsibilities on an interim basis, and the filing does not name a permanent successor.

Key points

  • Departure of Senior Vice President and Chief Commercial Officer Cindy Reiss-Clark, effective March 7, 2025
  • Aileen Kinsella, Head of Proprietary Product Sales, will manage leadership responsibilities on an interim basis
  • Filing does not state reasons for the departure or name a permanent replacement
  • Company announced the departure on March 7, 2025; the 8-K was filed March 11, 2025

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECMar 11, 2025, 4:08 PM ET
Accession number0000105770-25-000019

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.